Physician profile
Jamil Dihu
NPI 1154508570
$83,352.28
in general payments reported to CMS, 2019-2025
25 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $11K · 2021: $15K · 2022: $8,158 · 2023: $8,292 · 2024: $478 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,000 · Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,000.00 |
| Food and Beverage | $1,913.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $66,910.46 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Abbott Laboratories | $7,644.49 | 2019-2025 | Cardiomems, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,402.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $376.91 | 2019-2020 | |
| Abiomed | $318.55 | 2023-2024 | Impella |
| Penumbra, INC. | $285.57 | 2023-2024 | Indigo System |
| Pfizer INC. | $246.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $200.37 | 2019 | |
| Amgen INC. | $183.33 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $137.88 | 2019 | |
| Amarin Pharma, INC. | $132.35 | 2019 | |
| Astellas Pharma US INC | $125.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $78.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.32 | 2019 | |
| Merck Sharp & Dohme LLC | $43.44 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $40.81 | 2019 | |
| Biotronik INC. | $37.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.67 | 2019 | |
| Akcea Therapeutics, INC. | $19.35 | 2019 | |
| Biocompatibles, INC. | $18.88 | 2019 | |
| Csl Behring | $18.00 | 2019 | |
| Bardy Diagnostics, INC. | $14.54 | 2019-2020 | |
| Tactile Systems Technology INC | $13.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.98 | 2019 | |
| Cardinal Health 200 LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Dihu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.